On 16 April, 2023, during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, a hybrid […]
Category: Newsroom
COVIDRIVE´s first German study site has been activated
The Study Contributor Universitätsklinikum Frankfurt was activated on 05 April 2023.
First face-to-face COVIDRIVE Steering Committee meeting
On November 14th and 15th, 2022, the city of Valencia became the epicentre of COVIDRIVE Partnership discussions. The members of the COVIDRIVE Steering Committee (SC) connected to share the vaccine company-specific COVID-19 vaccine effectiveness interim results, to review all progress made and to brainstorm about vaccination preparedness and sustainability of the COVIDRIVE consortium. The group met at the Hotel Las Arenas and went through a packed two-day agenda.
New public-private partnership COVIDRIVE to assess brand-specific COVID-19 vaccine effectiveness in Europe
19/07/2021 – A new public-private partnership – COVIDRIVE – announced today that it will begin studies to assess the effectiveness of multiple COVID-19 vaccines in Europe to support the region’s public health response and to address the vaccine companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small medium enterprises and vaccine companies, including FISABIO (Spain), P95 (Belgium), THL (Finland), AstraZeneca (UK), CureVac (Germany), Janssen (Belgium), Sanofi-Pasteur (France) and GSK (Belgium).